Published on Medical Design Technology (http://www.mdtmag.com)

Home > Millennium, Seattle Genetics start trial of cancer drug

Millennium, Seattle Genetics start trial of cancer drug

Mass High Tech: The Journal of New England Technology

Millennium: The Takeda Oncology Company, of Cambridge and Seattle Genetics Inc. of Bothell, Wash., said today that they have started a Phase 3 clinical trial [1] to evaluate Adcetris, a drug candidate they are jointly developing for patients with CD30-expressing relapsed cutaneous T-cell lymphoma. Cutaneous T-cell lymphoma is a group of non-Hodgkin lymphomas that are cancers of the T lymphocytes (a type of white blood cell) mainly affecting the skin but that can also involve the blood, lymph nodes and/or internal organs in patients with advanced disease.

SOURCE [2]

Source URL (retrieved on 05/23/2013 - 12:21pm): http://www.mdtmag.com/news/2012/05/millennium-seattle-genetics-start-trial-cancer-drug

Links:
[1] http://www.businesswire.com/news/home/20120507005643/en/Millennium-Seattle-Genetics-Initiate-Global-Phase-3
[2] http://www.masshightech.com/stories/2012/05/07/daily10-Millennium-Seattle-Genetics-start-trial-of-cancer-drug.html